Benzoxazepin PI3K inhibitor compounds and methods of use

Patent metadata

Field	Value
Publication number	US-9670228-B2
Application number	US-201615368937-A
Country	US
Kind code	B2
Filing date	Dec 5, 2016
Priority date	Sep 28, 2009
Publication date	Jun 6, 2017
Grant date	Jun 6, 2017

Abstract

Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

First claim

We claim:

1. A process for preparing 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide, compound 196, having the structure:

comprising reacting 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoic acid, compound 251, having the structure:

with NH 4 Cl and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (HATU) to form compound 196.

2. The process of claim 1 wherein compound 251 is prepared by reacting ethyl 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoate, compound 412, having the structure:

with lithium hydroxide in water to form compound 251.

3. The process of claim 2 wherein compound 412 is prepared by reacting 9-bromo-2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine, compound 411, having the structure:

and ethyl 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate, having the structure:

under palladium catalyzed Suzuki coupling conditions to form compound 412.

4. The process of claim of claim 3 wherein the palladium catalyzed Suzuki coupling conditions comprise Pd(dppf)Cl2.

Assignees

• Genentech Inc

Inventors

• Blaquiere Nicole
• Do Steven
• Dudley Danette
• FOLKES Adrian
• Heald Robert
• Heffron Timothy
• Jones Mark
• Kolesnikov Aleksandr
• Ndubaku Chudi
• Olivero Alan G
• Price Stephen
• Staben Steven
• Wang Lan

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P37/04

  Immunostimulants · CPC title